# Scientia Ventures

Scientia Ventures is a Venture Capital based in New York, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** One Liberty Plaza, 46th Floor, New York, NY 10006, United States
- **Founded:** 2006
- **Assets under management:** Undisclosed
- **Website:** www.scientiavc.com
- **LinkedIn:** https://www.linkedin.com/company/scientia-ventures

## Regulatory record

- **Reports private funds:** No

## About

Scientia Ventures is a healthcare venture capital firm focused on life sciences and healthcare investments. The firm invests globally in various healthcare sectors, including new businesses and royalties on developed drugs. As of 2025, Scientia Ventures has made 39 investments, including a Series B - III investment in ZetaGen Therapeutics on November 12, 2025.

## Sectors

- Digital Health
- Life Sciences
- AgriTech & FoodTech

## Questions

### How does Scientia Ventures source and build its portfolio companies?

Scientia follows a dual-track model: it builds new companies around innovations its team identifies internally, and it partners with existing companies to accelerate growth and commercialization. The firm's partners draw on their own operating and scientific networks to source deals. This blend of venture formation and traditional early-stage investing gives it a proprietary pipeline concentrated on breakthroughs in computational biology and drug development.

### What investment stages does Scientia Ventures typically target?

The firm invests at the early-to-mid stage, spanning seed, start-up, and subsequent clinical and commercial inflection points. Its portfolio includes companies at various stages, from pre-revenue drug developers to publicly traded royalty platforms like Royalty Pharma. The focus remains on novel life-science technologies with the potential for radical change.

### Which sectors does Scientia Ventures focus on?

Scientia concentrates exclusively on healthcare, with a specific emphasis on computational biology and chemistry, the digitization of medicine, traditional drug development, and, through Cibus, precision gene editing for agriculture. It does not invest outside life-science and adjacent agri-tech applications.

### Has Scientia Ventures produced public-market exits?

Yes. The firm notes five IPOs from its 31-company portfolio. Named public portfolio holdings include Royalty Pharma, ADC Therapeutics, and Intra-Cellular Therapies. These exits span the royalty-financing, oncology, and neuroscience subsectors.

### Does Scientia Ventures participate in fund commitments or only direct deals?

Scientia makes direct equity investments through its fund vehicles rather than committing capital as a limited partner to other venture funds. Its strategy is built around active involvement in the strategic and commercial direction of the companies it backs, which aligns with a direct-only, active-management posture.

### Who manages investment decisions at Scientia Ventures?

Scientia does not publicly name its individual partners or investment committee. It describes its team collectively as a group with domain expertise across healthcare, finance, and intellectual property, many of whom are former life-science founders, operators, and CEOs. Decision-making authority and internal committee structure are not disclosed.

## Related profiles

- [Sciens Capital Management](https://altss.com/profile/sciens-capital-management)
- [Scientifica Venture Capital](https://altss.com/profile/scientifica-venture-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/scientia-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology